<DOC>
	<DOCNO>NCT00423995</DOCNO>
	<brief_summary>This study LMC , phenylephrine , placebo subject SAR . There three visit : At Visit 1 , subject evaluate participation , qualify , attend Visit 2 priming . At Visit 2 , ragweed pollen fed continuously dispense environmental exposure unit induce allergic reaction . Pollen count monitor recorded . During prim visit ( ) , subject evaluate determine qualify . If qualify , return Visit 3 , ragweed pollen fed continuously dispense environmental exposure unit induce allergic reaction . Pollen count monitor record Priming Session . Subjects complete symptom evaluation qualify , receive study medication remain environmental exposure unit symptom evaluate 8 hour dose . PNIF evaluate treatment session . Four nasal symptom ( rhinorrhea , nasal congestion , sneeze , nasal itch ) three non-nasal symptom ( itching/burning eye , tearing/watery eye , itch ears/palate ) evaluate . Adverse event collect throughout study assess safety tolerability , vital sign collect Visit 1 end Visit 3 .</brief_summary>
	<brief_title>Effect Loratadine/Montelukast Combination Congestion SAR Patients Exposed Pollen EEU ( Study P04822 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Ages 18 year great , either sex , race . A history SAR due ragweed least two consecutive ragweed season , diagnose investigator , another physician , subjectprovided history . Positive skin prick test ragweed allergen use EEU , unless previously do within 12 month Minimum score ( diary evaluation time ) must achieve pollen exposure Priming Visit Treatment Visit : A negative urine pregnancy test Screening prior randomization Treatment Visit female subject childbearing potential . Use medically accept method birth control . In judgment investigator , good health freedom clinically significant disease ( SAR ) would interfere study schedule procedure , compromise subject 's safety . The appropriate washout time prohibited medication . Pregnancy , intention become pregnant , lactation . A situation condition , opinion investigator , may interfere optimal participation study . Use investigational drug , include placebo , within 30 day Screening duration study . Current participation clinical study . Staff personnel directly involve study . Dependence ( opinion investigator ) upon nasal , oral , ocular decongestant , nasal topical antihistamine , nasal steroid . Nasal structural abnormality , include large nasal polyp mark septal deviation , cause great 50 % obstruction nasal airflow . Previous enrollment ( ie , sign informed consent ) study . History rhinitis medicamentosa . A history anaphylaxis severe serious reaction skin test . A known potential hypersensitivity , allergy , idiosyncratic reaction study drug excipients . Narrowangle glaucoma , increase intraocular pressure , urinary retention , hypertension , severe coronary artery disease , ischemic heart disease , diabetes mellitus , hyperthyroidism , renal impairment , prostatic hypertrophy ; current treatment monoamine oxidase ( MAO ) inhibitor . An upper low respiratory tract infection within 28 day ( 4 week ) Priming ( Visit 2 ) thereafter. ) . History positive test HIV , TB ( due vaccination ) , hepatitis B ( due vaccination ) C. Asthma require medication occasional ( &lt; = 3 us per week ) use inhale shortacting beta2 agonist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>